Dementia - STAT

The Readout LOUD By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Pfizer’s Covid-19 vaccine data, the FDA’s Alzheimer’s quandary, and how to think like a biostatistician

By Damian Garde, Meg Tirrell, and Adam Feuerstein

Listen: Bracing for a pandemic winter, Biogen’s fortune at the FDA, and remembering a remarkable 12-year-old

The Readout LOUD By Damian Garde and Adam Feuerstein

Listen: How the FDA thinks about Covid-19 vaccines, biotech’s SPAC fascination, & Biogen’s case in Alzheimer’s

Pharmalot By Ed Silverman

When off-label may mean off-target: How would doctors and insurers navigate demand for a new, narrow Alzheimer’s drug?

Health By Andrew Joseph

Her father developed dementia. She made a documentary — a surreal, hilarious one — about the end of his life

Health By Associated Press

Scientists get closer to blood test for Alzheimer’s disease

Alzheimer's neuron network with amyloid plaques

Biotech By Kate Sheridan

As biotech drifts from amyloid hypothesis for Alzheimer’s, some see reason to cling on

Pharmalot By Ed Silverman

Pharmalittle: Administration mishandled initial remdesivir distribution; AstraZeneca lung cancer drug shows big benefit

Pharmalot By Ed Silverman

Pharmalittle: Biogen delays Alzheimer’s drug filing; BARDA head leaves amid shakeup

Biotech By Damian Garde, Rebecca Robbins, and Adam Feuerstein

AC Immune bets that its Alzheimer’s trial design could provide a cleaner test of the amyloid hypothesis

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: Fauci’s star turn, the latest on coronavirus, and an under-the-radar Alzheimer’s drug

In the Lab By Sharon Begley

They have ‘Alzheimer’s brains’ but no symptoms. A new wave of drug developers wants to know why

Pharmalot By Ed Silverman

Rising out-of-pocket costs for dementia and neuropathy drugs lower patient adherence

First Opinion By Donna Jackson Nakazawa

Microglia: a new target in the brain for depression, Alzheimer’s, and more?

Biotech By Adam Feuerstein, Matthew Herper, and Damian Garde

At JPM, a debate on Alzheimer’s disease, some family drama in oncology, and a beaten-down biotech

First Opinion By Peter B. Bach

What roulette and basketball can teach Biogen about aducanumab

Health Tech By Casey Ross

Pear Therapeutics licenses voice biomarkers for dementia and psychiatric disorders

Biotech By Jonathan Saltzman — Boston Globe

An uncommon form of dementia hits at a younger age. Drug makers are searching for a treatment

Don't Miss By STAT staff

What will 2020 bring for medicine and science? We asked 16 leaders for predictions

In the Lab By Sharon Begley

Unorthodox Alzheimer’s researcher Robert Moir dies at age 58

Don't Miss By Alissa Ambrose

‘You keep loving each other’: A window into dementia at the end of a lifelong partnership

The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Listen: Biogen’s big reveal, hot takes on Alzheimer’s, & the science of one-eyed sheep

First Opinion By Eric Chess

Step aside, biomarkers. Look to the bank account for early signs of dementia

Biotech By Rebecca Robbins

4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

Health By Elizabeth Cooney

Most Read

Using human brain tissue in lab dishes, researchers show herpes link to Alzheimer’s

Role of seizures in Alzheimer’s disease is gaining overdue attention

Aducanumab: the beginning of the end of Alzheimer’s disease?

Before you send your spit to 23andMe, what you need to know

Aducanumab isn’t the simple solution to the complicated Alzheimer’s crisis

‘I just want to reboot my brain’: How dementia gripped Robin Williams

Did dementia cause Robin Williams’ suicide? Unlikely, experts say

I used to work on Biogen’s Alzheimer’s drug. Is the company spinning bad data?

All Coverage

Listen: Pfizer’s Covid-19 vaccine data, the FDA’s Alzheimer’s quandary, and how to think like a biostatistician

Listen: Bracing for a pandemic winter, Biogen’s fortune at the FDA, and remembering a remarkable 12-year-old

Listen: How the FDA thinks about Covid-19 vaccines, biotech’s SPAC fascination, & Biogen’s case in Alzheimer’s

When off-label may mean off-target: How would doctors and insurers navigate demand for a new, narrow Alzheimer’s drug?

Her father developed dementia. She made a documentary — a surreal, hilarious one — about the end of his life

Scientists get closer to blood test for Alzheimer’s disease

As biotech drifts from amyloid hypothesis for Alzheimer’s, some see reason to cling on

Pharmalittle: Administration mishandled initial remdesivir distribution; AstraZeneca lung cancer drug shows big benefit

Pharmalittle: Biogen delays Alzheimer’s drug filing; BARDA head leaves amid shakeup

AC Immune bets that its Alzheimer’s trial design could provide a cleaner test of the amyloid hypothesis

Listen: Fauci’s star turn, the latest on coronavirus, and an under-the-radar Alzheimer’s drug

They have ‘Alzheimer’s brains’ but no symptoms. A new wave of drug developers wants to know why

Rising out-of-pocket costs for dementia and neuropathy drugs lower patient adherence

Microglia: a new target in the brain for depression, Alzheimer’s, and more?

At JPM, a debate on Alzheimer’s disease, some family drama in oncology, and a beaten-down biotech

What roulette and basketball can teach Biogen about aducanumab

Pear Therapeutics licenses voice biomarkers for dementia and psychiatric disorders

An uncommon form of dementia hits at a younger age. Drug makers are searching for a treatment

What will 2020 bring for medicine and science? We asked 16 leaders for predictions

Unorthodox Alzheimer’s researcher Robert Moir dies at age 58

‘You keep loving each other’: A window into dementia at the end of a lifelong partnership

Listen: Biogen’s big reveal, hot takes on Alzheimer’s, & the science of one-eyed sheep

Step aside, biomarkers. Look to the bank account for early signs of dementia

4 questions key to making sense of new data on Biogen’s resurrected Alzheimer’s drug

Some brain-boosting supplements contain an unapproved drug that could harm users, study warns